{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:20:05Z","timestamp":1783948805283,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clineuro.2021.106889","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T18:29:46Z","timestamp":1628879386000},"page":"106889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions"],"prefix":"10.1016","volume":"209","author":[{"given":"Inc\u0131 Sule","family":"Ozer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muge","family":"Kuzu Kumcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Tezcan Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhittin Cenk","family":"Akbostanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2021.106889_bib1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jnnp.73.5.604","article-title":"Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia","volume":"73","author":"Dressler","year":"2002","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2021.106889_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","article-title":"Dose standardisation of botulinum toxin","volume":"59","author":"Marion","year":"1995","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2021.106889_bib3","first-page":"11","article-title":"Immunological aspects of Botox\u00ae, Dysport\u00ae and Myobloc\/Neurobloc\u00ae, Eur","volume":"13","author":"Dressler","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2021.106889_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","article-title":"Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study","volume":"20","author":"Marchetti","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.clineuro.2021.106889_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079905X36396","article-title":"Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm","volume":"21","author":"Bihari","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.clineuro.2021.106889_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10072-011-0672-7","article-title":"Retrospective evaluation of the dose equivalence of Botox\u00ae and Dysport\u00ae in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story","volume":"33","author":"Bentivoglio","year":"2012","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clineuro.2021.106889_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","article-title":"Comparison of the spread of three botulinum toxin type A preparations","volume":"304","author":"Kerscher","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.clineuro.2021.106889_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WNF.0b013e3182711fc0","article-title":"Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia","volume":"35","author":"Rystedt","year":"2012","journal-title":"Clin. Neuropharm."},{"key":"10.1016\/j.clineuro.2021.106889_bib9","first-page":"459","article-title":"Respective potencies of Botox and Dysport: a double bind, randomised, cross over study in cervical dystonia","volume":"72","author":"Ranoux","year":"2002","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2021.106889_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mds.26085","article-title":"Dysport and Botox at ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study","volume":"30","author":"Yun","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.clineuro.2021.106889_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF03033932","article-title":"No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm","volume":"9","author":"Lorenzano","year":"2006","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.clineuro.2021.106889_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.autneu.2004.11.005","article-title":"Botulinum toxin A (Botox\u00ae) and sweating-dose efficacy and comparison to other BoNT preparations","volume":"117","author":"Schlereth","year":"2005","journal-title":"Auton. Neurosci."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721004182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721004182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:37:49Z","timestamp":1759588669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846721004182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":12,"alternative-id":["S0303846721004182"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106889","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106889"}}